---
title: Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria
date: '2024-10-07'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39374533/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241007200551&v=2.18.0.post9+e462414
source: Blood
description: Iptacopan, a novel oral Factor B inhibitor, recently obtained FDA approval
  for treating paroxysmal nocturnal hemoglobinuria, a rare blood disorder characterized
  by persistent complement-mediated hemolytic anemia. The standard-of-care (SOC) has
  traditionally relied on complement C5 inhibitors eculizumab and ravulizumab, which
  are limited by persistent anemia from extravascular hemolysis and requirement for
  intravenous infusion. Recent publication of phase 3 studies in this arena ...
disable_comments: true
---
Iptacopan, a novel oral Factor B inhibitor, recently obtained FDA approval for treating paroxysmal nocturnal hemoglobinuria, a rare blood disorder characterized by persistent complement-mediated hemolytic anemia. The standard-of-care (SOC) has traditionally relied on complement C5 inhibitors eculizumab and ravulizumab, which are limited by persistent anemia from extravascular hemolysis and requirement for intravenous infusion. Recent publication of phase 3 studies in this arena ...